Half-year trading update

Paris, France, and Manchester, UK - 29 July 2025 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces an unaudited trading update for the six months ended 30 June 2025.

Financial Highlights

• Unaudited Group statutory revenue for H1 2025 expected to be circa £9.8 million (H1 2024: £10.0 million - restated to remove any IT-IS International revenue due to its treatment under IFRS 5)

o The underlying Group revenue has grown by circa 2% (4% on a constant currency basis), excluding the impact of the Taiwan service laboratory divestment

• Encouraging growth delivered by the Company's clinical segment, generating sales of £6.9 million
• NIPT technologies up over 10% year-on-year to £2.4 million
• Geographically, the APAC region achieved year-on-year growth of circa 9%, driven by the continued strong demand for the Company's Reproductive Health range of products

o Cash position at 30 June 2025 was £23.8 million (31 December 2024: £30.5 million), and the Group remains debt free and confident that the cash runway is sufficient to reach EBITDA profitability

Post Period Highlights

• LightBench® Discover, a high-precision 3-in-1 instrument for genomic research labs conducting long-read sequencing, was successfully launched in July 2025

Commenting Lyn Rees, Chief Executive Officer, said: "We are pleased with the Company's performance to date, following an extensive period of restructuring and consolidation and remain focused on executing growth to see the Company through to EBITDA profitability. We are proud to announce the successful launch of LightBench® Discover, putting Novacyt at the forefront of genomic research."